CA2321026A1
(en)
*
|
1998-03-09 |
1999-09-16 |
Zealand Pharmaceuticals A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
US7550425B2
(en)
|
2000-06-16 |
2009-06-23 |
Zealand Pharma A/S |
Diuretic peptide conjugates
|
ATE480561T1
(de)
|
2004-10-19 |
2010-09-15 |
Lonza Ag |
Verfahren zur festphasen-peptidsynthese
|
WO2006117565A2
(en)
|
2005-05-04 |
2006-11-09 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (glp-2) analogues
|
GB0514071D0
(en)
|
2005-07-07 |
2005-08-17 |
Zealand Pharma As |
N- or C- terminally modified small peptides
|
WO2007060860A1
(ja)
*
|
2005-11-22 |
2007-05-31 |
Nihon University |
ピロールイミダゾールポリアミドの固相自動合成
|
ES2443242T3
(es)
|
2005-12-23 |
2014-02-18 |
Zealand Pharma A/S |
Compuestos modificados miméticos de lisina
|
JP5295785B2
(ja)
|
2006-02-20 |
2013-09-18 |
エファ・ユニバーシティ・インダストリー・コラボレイション・ファウンデイション |
細胞膜透過性ペプチド
|
CN101437836B
(zh)
*
|
2006-03-29 |
2013-07-24 |
株式会社糖锁工学研究所 |
肽的硫酯化合物的制造方法
|
UA102506C2
(ru)
|
2006-11-08 |
2013-07-25 |
Зиланд Фарма А/С |
Селективные аналоги глюкагоноподобного пептида-2 (glp-2)
|
US7994122B2
(en)
|
2007-06-15 |
2011-08-09 |
Zealand Pharma A/S |
Glucagon analogues
|
WO2010070251A1
(en)
|
2008-12-15 |
2010-06-24 |
Zealand Pharma A/S |
Glucagon analogues
|
JP5635531B2
(ja)
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
AU2008365559B2
(en)
|
2008-12-15 |
2016-02-25 |
Zealand Pharma A/S |
Glucagon analogues
|
DK2370460T3
(da)
|
2008-12-15 |
2014-08-04 |
Zealand Pharma As |
Glucagon analoger
|
ES2537287T3
(es)
|
2009-07-13 |
2015-06-05 |
Zealand Pharma A/S |
Análogos de glucagón acilados
|
CN107129538B
(zh)
|
2010-04-27 |
2021-07-16 |
西兰制药公司 |
Glp-1受体激动剂和胃泌素的肽缀合物及其用途
|
UY33462A
(es)
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
CN103068841A
(zh)
|
2010-06-24 |
2013-04-24 |
西兰制药公司 |
胰高血糖素类似物
|
PE20140969A1
(es)
|
2011-01-20 |
2014-07-24 |
Zealand Pharma As |
Combinacion de analogos del glucagon acilados con analogos de insulina
|
WO2013064669A1
(en)
|
2011-11-03 |
2013-05-10 |
Zealand Pharma A/S |
Glp-1 receptor agonist peptide gastrin conjugates
|
PE20142113A1
(es)
|
2011-12-23 |
2014-12-03 |
Zealand Pharma As |
Analogos de glucagon
|
WO2013098408A1
(en)
|
2011-12-30 |
2013-07-04 |
Zealand Pharma A/S |
Glucagon and cck receptor agonist peptide conjugates
|
AR089860A1
(es)
|
2012-02-03 |
2014-09-24 |
Zealand Pharma As |
Analogos de la grelina
|
EP2844669B1
(de)
|
2012-05-03 |
2018-08-01 |
Zealand Pharma A/S |
Gip-glp-1-dualagonistenverbindungen und verfahren
|
EA028929B1
(ru)
|
2012-05-03 |
2018-01-31 |
Зилэнд Фарма А/С |
Аналоги глюкагоноподобного пептида-2 (glp-2)
|
AU2013295035B2
(en)
|
2012-07-23 |
2017-08-03 |
Zealand Pharma A/S |
Glucagon analogues
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
PT2970487T
(pt)
|
2013-03-12 |
2020-06-17 |
Molecular Templates Inc |
Proteínas citotóxicas compreendendo regiões de ligação de direcionamento para células e regiões de subunidades de toxina a shiga para a morte seletiva de tipos específicos de células
|
US9169287B2
(en)
|
2013-03-15 |
2015-10-27 |
Massachusetts Institute Of Technology |
Solid phase peptide synthesis processes and associated systems
|
US9695214B2
(en)
|
2013-03-15 |
2017-07-04 |
Massachusetts Institute Of Technology |
Solid phase peptide synthesis processes and associated systems
|
SG11201506885UA
(en)
|
2013-03-21 |
2015-09-29 |
Sanofi Aventis Deutschland |
Synthesis of cyclic imide containing peptide products
|
AU2014234400B2
(en)
|
2013-03-21 |
2017-11-16 |
Sanofi-Aventis Deutschland Gmbh |
Synthesis of hydantoin containing peptide products
|
RS57632B1
(sr)
|
2013-10-17 |
2018-11-30 |
Zealand Pharma As |
Acilovani analozi glukagona
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
AU2014345569B2
(en)
|
2013-11-06 |
2020-08-13 |
Zealand Pharma A/S |
GIP-GLP-1 dual agonist compounds and methods
|
EP3066117B1
(de)
|
2013-11-06 |
2019-01-02 |
Zealand Pharma A/S |
Dreifache glucagon-glp-1-gip-agonistenverbindungen
|
US10435474B2
(en)
|
2013-12-24 |
2019-10-08 |
Ossianix, Inc. |
Baff selective binding compounds and related methods
|
AU2015209063C1
(en)
|
2014-01-27 |
2020-06-25 |
Molecular Templates, Inc. |
MHC class I epitope delivering polypeptides
|
MX2016011821A
(es)
|
2014-03-11 |
2017-04-27 |
Molecular Templates Inc |
Proteinas que comprenden regiones efectoras de subunidad a de toxina shiga proximas a amino terminal y regiones de union de tipo inmunoglobulina de direccionamiento selectivo celular.
|
EP3825327A1
(de)
|
2014-03-11 |
2021-05-26 |
Molecular Templates, Inc. |
Proteine mit bindungsregionen, shiga-toxin-a-untereinheiteffektorregionen und carboxyterminale, endoplasmatische retikulumlokalisierungssignalmotive
|
ES2919749T3
(es)
|
2014-06-11 |
2022-07-28 |
Molecular Templates Inc |
Moléculas dirigidas a células citotóxicas resistentes a la escisión por proteasa
|
EP3160995A2
(de)
|
2014-06-26 |
2017-05-03 |
Ossianix Inc. |
Halbsynthetische ammenhai-vnar-bibliotheken zur herstellung und verwendung von verbindungen mit selektiver bindung
|
EP3985016A1
(de)
|
2014-10-29 |
2022-04-20 |
Zealand Pharma A/S |
Gip-agonisten-verbindungen und -verfahren
|
CA2967830A1
(en)
|
2014-11-14 |
2016-05-19 |
Ossianix, Inc. |
Tfr selective binding compounds and related methods
|
AU2016215205B2
(en)
|
2015-02-05 |
2021-10-21 |
Molecular Templates, Inc. |
Multivalent CD20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
|
CA2979950A1
(en)
|
2015-03-18 |
2016-09-22 |
Zealand Pharma A/S |
Amylin analogues
|
GB201506380D0
(en)
|
2015-04-15 |
2015-05-27 |
Serodus Asa |
Materials and methods for treatment of pulmonary hypertension
|
EP3283507B8
(de)
|
2015-04-16 |
2019-11-13 |
Zealand Pharma A/S |
Acyliertes glucagon-analogon
|
LT3303373T
(lt)
|
2015-05-30 |
2020-07-10 |
Molecular Templates, Inc. |
Deimunizuoto shiga toksino a subvieneto karkasai ir juos apimančios ląstelės taikinio molekulės
|
KR20180030085A
(ko)
|
2015-07-26 |
2018-03-21 |
몰레큘러 템플레이츠, 인코퍼레이션. |
시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
|
CA2999031A1
(en)
|
2015-09-17 |
2017-03-23 |
Massachusetts Institute Of Technology |
Methods and systems for solid phase peptide synthesis
|
WO2018031424A1
(en)
|
2016-08-06 |
2018-02-15 |
Ossianix, Inc. |
In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
|
TWI784968B
(zh)
|
2016-09-09 |
2022-12-01 |
丹麥商西蘭製藥公司 |
澱粉素類似物
|
WO2018104559A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
WO2018104558A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
JP2020500890A
(ja)
|
2016-12-09 |
2020-01-16 |
ジーランド・ファーマ・ア/エス |
Glp−1/glp−2二重アゴニスト
|
WO2018103868A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
ES2979184T3
(es)
|
2016-12-09 |
2024-09-24 |
Zealand Pharma As |
Agonistas duales de glp-1/glp-2 acilados
|
US20200024312A1
(en)
|
2017-01-25 |
2020-01-23 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
WO2019089395A1
(en)
|
2017-11-02 |
2019-05-09 |
Ossianix, Inc. |
Improved tfr-selective binding peptides capable of crossing the blood brain barrier
|
KR20200135797A
(ko)
|
2018-02-27 |
2020-12-03 |
제트피 에스피브이 3 케이/에스 |
콤프스타틴 유사체 및 이들의 의학적 용도
|
CN110612117B
(zh)
|
2018-04-17 |
2024-04-12 |
分子模板公司 |
包含去免疫化的志贺毒素a亚基支架的her2靶向分子
|
WO2019246288A1
(en)
|
2018-06-22 |
2019-12-26 |
Ossianix, Inc. |
Anti-cd98hc vnars for crossing the blood brain barrier and type iv vnar libraries
|
WO2020056327A1
(en)
|
2018-09-14 |
2020-03-19 |
Ossianix, Inc. |
Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
CA3127660A1
(en)
|
2019-01-23 |
2020-07-30 |
Millennium Pharmaceuticals, Inc. |
Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors
|
US20220202704A1
(en)
|
2019-06-14 |
2022-06-30 |
Zealand Pharma A/S |
Pharmaceutical parenteral composition of dual glp1/2 agonist
|
US20220306695A1
(en)
|
2019-08-27 |
2022-09-29 |
Zp Spv 3 K/S |
Compstatin analogues and their medical uses
|
WO2021055816A1
(en)
|
2019-09-18 |
2021-03-25 |
Molecular Templates, Inc. |
Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
|
EP4031162A1
(de)
|
2019-09-20 |
2022-07-27 |
Zealand Pharma A/S |
Kv1.3-blocker
|
WO2021102445A1
(en)
|
2019-11-24 |
2021-05-27 |
Molecular Templates, Inc. |
Uses of cd20-binding molecules and additional therapeutic agents
|
WO2021198196A1
(en)
|
2020-03-30 |
2021-10-07 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
WO2021198195A1
(en)
|
2020-03-30 |
2021-10-07 |
Zealand Pharma A/S |
Agonist combination
|
CA3185730A1
(en)
|
2020-07-16 |
2022-01-20 |
Anne Pernille Tofteng SHELTON |
Inhibitors of complement factor c3 and their medical uses
|
WO2022103769A1
(en)
|
2020-11-11 |
2022-05-19 |
Ossianix, Inc. |
High affinity human and monkey specific tfr-1 vnars
|
CN116723850A
(zh)
|
2020-12-16 |
2023-09-08 |
西兰制药公司 |
Glp-1/glp-2双重激动剂的药物组合物
|
CN116710114A
(zh)
|
2020-12-16 |
2023-09-05 |
西兰制药公司 |
Glp-1/glp-2双重激动剂的药物组合物
|
WO2022129305A1
(en)
|
2020-12-16 |
2022-06-23 |
Zealand Pharma A/S |
Pharmaceutical composition of glp-1/glp-2 dual agonists
|
WO2022175410A1
(en)
|
2021-02-18 |
2022-08-25 |
Zealand Pharma A/S |
Composition for treating short bowel syndrome
|
CA3213295A1
(en)
|
2021-03-17 |
2022-09-22 |
Molecular Templates, Inc. |
Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
|
AU2022245193A1
(en)
|
2021-03-23 |
2023-09-07 |
Zealand Pharma A/S |
Kv1.3 blockers
|
WO2022260877A1
(en)
|
2021-06-07 |
2022-12-15 |
Ossianix, Inc. |
Shark vnars for treating covid-19
|
CA3221829A1
(en)
|
2021-06-18 |
2022-12-22 |
Weibing LIU |
Glucagon analog and medical use thereof
|
EP4388001A1
(de)
|
2021-08-17 |
2024-06-26 |
Ossianix, Inc. |
Deimmunisierte vanar-domänen und gerüste
|
IL311166A
(en)
|
2021-09-03 |
2024-04-01 |
Zealand Pharma As |
dosage regimen
|
AU2022402440A1
(en)
|
2021-12-01 |
2024-05-30 |
Zealand Pharma A/S |
Peptide inhibitors of interleukin-23 receptor
|
WO2024068848A1
(en)
|
2022-09-28 |
2024-04-04 |
Zealand Pharma A/S |
Methods for treating obesity
|
WO2024083919A1
(en)
|
2022-10-18 |
2024-04-25 |
Zealand Pharma A/S |
Inhibitors
|
WO2024168411A1
(pt)
*
|
2023-02-15 |
2024-08-22 |
Proteimax Bio Technology Israel Ltd |
Aditivo de alimento e/ou suplemento alimentar, processo de obtenção, formulação de alimento funcional e/ou suplemento alimentar, uso
|